LINICIANS are now using endoluminal stents with increasing frequency to treat medically refractory or severe symptomatic intracranial atherosclerotic disease. 2, 14, 20, 30, 37 When left untreated after failed medical therapy, severe stenoses may lead to morbidity rates as high as 80%, with stroke rates as high as 10%. 5, 11, 29, 46 In one recent study, more than half of the patients with greater than 50% stenosis had recurrent symptoms, despite optimal antithrombotic and antiplatelet therapies.
disease has increased in popularity, yet no in vivo model has been developed to examine the response of cerebral vessels to the implantation of these devices. Although vascular response to stent implantation in the coronary and peripheral vasculature has been studied extensively in numerous in vivo models, we cannot assume that a similar response exists in the arteries of the central nervous system. Intracranial vessels differ substantially from peripheral and coronary vessels in that they lack robust adventitia. These thinwalled vessels are composed of a higher percentage of smooth-muscle cells, which are believed to be responsible for restenosis. 4, 9, 10, 35 The authors report the results of a study in which the primary objective was to develop an intracranial in vivo model of stent implantation in dogs. To test the reproducibility and reliability of this model, the authors conducted a pilot study in which coated and uncoated stents were implanted in a blinded, randomized fashion to ascertain whether potential differences in cerebrovascular responses could be measured. To achieve this secondary objective, a limited number of stent implantations were performed using both heparin-coated and uncoated stents placed in the BAs of dogs. These experiments were motivated by the hypothesis that heparin-coated stents may impair platelet and thrombinmediated signaling of the cellular cascade responsible for thrombosis and cell proliferation on the stent matrix. 36, 41 Although heparin-coated devices have been shown to inhibit acute and subacute stent-related thrombosis and to decrease the incidence of restenosis in vivo in animal models of extracranial vessels, 1, 13, 21, 26, 33 the effects of drug-coated stents have not been studied in the intracranial circulation. 47 Another secondary aim of this study was to examine the histological effects of flow alterations resulting from "jailing" of brainstem perforating vessels after stent placement, which has not been previously investigated in live animals. Stent jailing is seen when the stent strut covers the ostium of a branch artery and causes immediate obstruction of flow to that vessel.
Materials and Methods
This study was approved by the University at Buffalo Animal Care and Use Committee in accordance with guidelines established by the Animal Welfare Act. 12 
Choice of Canine Model
For numerous reasons, dogs were chosen over pigs and other species for the animal model. Of greatest importance, canine vessels behave more like human vessels than do those of pigs with respect to vasospasm, recoil, neointimal proliferation, and thrombotic potential. 15, 34, 45 Additionally, dogs are less susceptible to spontaneous thrombosis of blood vessels than are other species because of a hypervascular fibrinolytic system. 27 This characteristic is especially important when endovascular devices are used to improve vessel patency. More importantly, the caliber and accessibility of canine vessels permit the replication of conditions similar to those encountered during intracranial stent implantation in humans. The diameter of the BA in the canine model approximates that of distal intracranial vessels in humans (~ 1.5-1.8 mm). The catheters and devices used in humans can be used in dogs. The arteries are easily accessible and can be easily removed and processed for histological analysis. 45 
Randomization Scheme
A predetermined order for the use of uncoated and heparin-coated stents was devised before the first one was implanted. The lead interventionists (E.I.L., A.S.B., and R.A.H.) were blinded to this scheme throughout the entire stent implantation procedure. The histopathologist (F.O.T.), histopathology technicians, and radiologist (R.A.A.) were also blinded to the stent properties. The devices used in this study were 2.25 ϫ 8-mm stainless steel, balloon-mounted heparincoated or uncoated BX Velocity stents (Cordis Corp., Miami Lakes, FL). These two types of stents are identical in appearance (Fig. 1) .
Endoluminal Stent Placement
Mongrel dogs, each weighing 15 to 25 kg, underwent diagnostic cerebral angiography after the induction of general anesthesia with 1.5 to 2.5% isoflurane. Baseline measurements were obtained of the BA lumen diameter along several points corresponding to the anticipated location of the stent. Dogs with arterial diameters measuring less than 1.4 mm were excluded from the study and returned to the housing facility; those with larger-diameter arteries underwent attempted stent placement.
A No. 6 French guide catheter was inserted into the cervical VA to the C-3 level by using standard cutdown access techniques. A microguidewire was then advanced through the guide catheter into the distal BA by using conventional roadmapping techniques. The stent was advanced over the wire, and, again using roadmapping techniques, was positioned distal to the junction of the VAs within the BA. In one animal, one stent was also placed in the distal ASA at the level of the foramen magnum, just proximal to the VBJ. This animal had a sufficiently large ASA that matched the size of the BA, enabling us to perform a dual stent placement, which allowed us to reduce the number of animals required for the study. Slow inflation methods were used to expand the stent to the minimum implantation diameter of approximately 1.9 mm (at 4-4.5 atm of pressure). After angiographic confirmation of stent expansion and delivery, the balloon-catheter system was withdrawn to a region proximal to the stent. Nitroglycerine (20-50 mg) was administered through the balloon catheter in the event of severe vasospasm (Fig. 2) . Repeated angiography was performed immediately after stent placement to determine the presence of extravasated contrast material and vessel patency.
After successful implantation of the device, the animals were revived and examined. In each case, the stent was intentionally oversized relative to the diameter of the arterial lumen to induce vessel injury and activate the cytological cascade leading to the inflammation-mediated vascular healing response (as is seen after plaque formation and rupture). This is not analogous to the clinical setting, in which stents are precisely sized to the diameter of the parent vessel as measured in nonstenotic segments.
Each animal received 2000 U heparin during the procedure and was maintained on aspirin (81 mg daily, initiated 1 day before stent implantation) throughout the 12-week follow-up period. Examinations were conducted daily to assess the presence of any neurological deficit.
Specimen Collection
Eight stents (three uncoated and five coated) were successfully delivered intracranially in seven animals (seven stents were placed in the BAs and one in the distal ASA adjacent to the foramen magnum, just proximal to the VBJ). At 12 weeks, repeated angiography was performed to document the presence or absence of in-stent stenosis. The animals were then killed in accordance with the recommendations of the American Veterinary Medicine Association Panel on Euthanasia. 6 Formalin (500 ml of 10% concentration) was then perfused through the guide catheter that had been previously placed in the VA for angiographic studies. A craniectomy was performed, and the brain and brainstem were removed en bloc, maintaining the integrity of the vertebrobasilar vessels (Fig. 3) . Microdissection techniques were used to remove the posterior cerebral vessels, which were then fixed in 10% formalin; the brain was placed in a separate container of 10% formalin.
Histological and Computer-Assisted Morphometric Analysis
The histopathologist and histology technicians were blinded to the type of stent (coated or uncoated). After en bloc removal of the brain and microdissection of the posterior circulation and circle of Willis, the specimens were then embedded in methyl methacrylate plastic (Sigma Chemical Co., St. Louis, MO) after dehydration in a graded series of ethanol. Using a Buehler Isomet saw (Buehler Ltd., Evanston, IL), serial sections of plastic-embedded specimens were obtained from the proximal to the distal end. All sections were polished and stained with metachromatic stain and inspected for perforating branches and technical suitability for measurement. Three to four cross-sections of stent-treated vessels sampled from along the length of the device, plus one from each of the adjacent untreated proximal and distal end segments, were measured and graded under a 4ϫ objective lens for various histological changes, including inflammation and intimal smooth-muscle cell infiltration.
Sigmascan morphometric software (Jandel Scientific, San Rafael, CA) was used to calculate measurements (described later) of arteries inspected through a Nikon Labophot compound microscope integrated to the light-emitting diode-illuminated cursor of a standard digitizing pad through a drawing tube attachment. Three different areas were measured: 1) artery area, the area (in square millimeters) delimited by the junction of the adventitia and the tunica media (external elastic membrane); 2) stent area, the area within the stent; and 3) lumen area, the area within the inner surface of the intima. Neointimal thickness (in millimeters), percentage of occlusion, and neointima/media ratio were calculated from these area measurements. Neointimal area was calculated by subtracting the area of the lumen from that of the stent. An inflammation score was assigned that was based on the presence of any significant inflammation surrounding the stent struts, as follows: 1) involvement of less than 25% of the artery; 2) involvement of 25% or more but less than 50% of the artery; and 3) involvement of 50% or more of the artery (Fig. 4) . 44 Intimal smooth-muscle cell content was scored according to the following scheme: 1) sparse density of smooth-muscle cells involving any portion of the artery or moderate infiltration less than the full thickness of the neointima involving less than 25% of the circumference of the artery; 2) moderate infiltration of less than the full thickness of the neointima involving 25% or more of the circumference of the artery or dense smooth-muscle cell content over the full thickness of the neointima involving less than 25% of the circumference of the artery; and 3) dense smooth-muscle cell content over the full thickness of the neointima involving 25% or more of the circumference of the artery. 44 The percentage of occlusion was calculated according to the following formula: % occlusion = 1 Ϫ (lumen area/stent area) ϫ 100.
Magnetic Resonance Imaging
For MR imaging of each formalin-fixed brain, T 2 -weighted (long repetition time-weighted) and gradient spin-echo imaging sequences were used to determine the presence or absence of infarction or hemorrhage. Imaging was directed to the brainstem, cerebellum, and posterior portions of the cortex, because each of these regions has a predominantly posterior circulation blood supply. All images were interpreted by a board-certified neuroradiologist (R.A.A.) who was blinded to the properties of the stent used in each specimen of the vasculature (Fig. 5) .
Statistical Analysis
For each stent placement, various histological and morphological parameters were measured in triplicate, with one measurement taken at each of three stent-implanted regions. These measurements were then averaged, as were similar reference measurements from two adjacent regions with stents. The mean values of these histological measurements were then calculated for both uncoated and heparincoated stents. Group means were compared with the use of t-tests for the analysis of unpaired data, and two-tailed probability values were calculated. A probability value of 0.05 or less was considered statistically significant. Values are graphically expressed as the mean Ϯ SEM. All statistics were calculated using the Instat statistical package (GraphPad Software, Inc., San Diego, CA).
Results

Stent Implantation Procedure
Stent placement in the BA was attempted in 12 mongrel dogs. Five animals suffered fatal vascular injuries as a result of either BA rupture or perforation of a branch vessel. Softer microguidewires (PVS; Precision Vascular Systems, West Valley City, UT, or Transcend EX; Boston Scientific, Natick, MA) were then used, and no further perforations occurred. Stent placement procedures were altered so that the devices were delivered over 3 to 5 minutes instead of within 1 minute, and no further BA ruptures occurred. Eight stents (three uncoated and five coated) were successfully placed intracranially in seven dogs (seven stents in the BA and one in the distal ASA adjacent to the foramen magnum, just proximal to the VBJ). The mean diameter of the BA lumen before stent implantation was 1.51 Ϯ 0.08 mm (mean Ϯ standard deviation, range 1.4-1.6 mm). Seven stents (in six animals) were removed at the end of the target follow-up period of 12 weeks, and one stent was removed 24 hours after implantation because of a brainstem perforating vessel injury resulting in lower-extremity paraparesis. This injury was caused by the inadvertent placement of the microguidewire in the perforating vessel and resulted in a small hole in the vessel, as evidenced by the presence of a transient extravascular blush of contrast material. The stent, vessels, and brain removed at 24 hours were prepared for histopathological and radiographic analyses. Histological analysis revealed the complete absence of endothelialization of the stent struts and intimal proliferation. The findings, however, were not included in any of the calculations comparing coated and uncoated devices, because the stent demonstrated no evidence of neointimal formation.
Follow-Up Angiography and MR Imaging
Follow-up angiography at 12 weeks demonstrated a normal angiographic lumen diameter through the treated portion and the immediately adjacent portion of the parent vessel in the six surviving animals (Fig. 6 ). All perforating vessels jailed by stents were patent on angiographic studies (Fig. 7) . Despite angiographically confirmed filling of visible perforating vessels originating from the treated segment of the BA, stenosis was noted at the origin of the left AICA during follow-up angiography in two animals, one from the group treated with coated stents and the other from the group treated with uncoated devices (Table 1) . These vessels filled normally, distal to their stenotic origins. In one of these dogs (Animal 2, uncoated stent group), pontine infarction was noted on MR imaging (Fig. 5 ). Despite these angiographic and MR imaging findings, no clinical sequelae were observed in any of the surviving animals.
Histopathological and Computer-Assisted Morphometric Analysis
The neointimal area (stent area Ϫ lumen area) was determined for the treated segments of the BA and the areas immediately adjacent to them in both the group receiving heparin-coated stents and that treated with uncoated stents ( Table 2 adventitia and the tunica media (external elastic membrane) was similar in both groups. Nevertheless, the mean neointimal area was 0.18 mm 2 in the group treated with heparincoated stents and 0.42 mm 2 in the group with uncoated devices. This reduction in neointimal proliferation was found to be statistically significant (p = 0.04). The neointima/media ratio was increased in the group treated with uncoated stents (p = 0.05), as was neointimal thickness (in millimeters, p = 0.04). The mean lumen area was similar in both groups, at 1.33 and 1.53 mm 2 in the dogs treated with coated and uncoated stents, respectively. The mean percentage of occlusion of the vessel lumen was 11.92% in the group treated with coated stents and 22.05% in the group with uncoated devices (p = 0.07). Segments of artery immediately adjacent to the stent demonstrated mean occlusion rates of 15.84 and 11.12% in the dogs treated with uncoated and coated stents, respectively. The mean intimal smooth-muscle cell proliferation score was 3 in the dogs that received uncoated stents and 1.6 in those with coated devices, indicating lower smooth-muscle cell density in the intima after implantation of a heparin-coated stent (Fig. 8) . Significant inflammation (a score of 3) was seen within the neointima in only one dog (Animal 5) that received an uncoated stent.
As shown in Figs. 9 and 10, when comparing results between the group treated with heparin-coated stents and the one treated with uncoated devices in the five animals that had a single stent placed in the BA and that were observed for 12 weeks thereafter, greater differences (reflecting a benefit of heparin-coated stents) were demonstrated in the group receiving single stents (compared with dogs receiving either one or two stents), with respect to neointimal area (p = 0.009), neointimal area/media ratio (p = 0.001), neointimal thickness (p = 0.002), and percentage of occlusion (p = 0.009). For these specific parameters, the values in the animal that received both a coated stent (BA) and an uncoated one (ASA) fell between those for the uncoated stents and the coated ones in animals receiving one stent. From this observation we infer that the interaction of the two stents created an environment in which the benefits of the heparin-coated stents were diminished by the uncoated ones.
Discussion
Medical Impact
Stroke is the third leading cause of death in the US, afflicting approximately 750,000 people annually. 3 Severe intracranial stenosis is responsible for an unknown percentage of these strokes and, when left untreated, may result in morbidity rates ranging from 50 to 80%. 11, 29, 46 Data from the Warfarin-Aspirin Symptomatic Intracranial Disease study demonstrate that patients with more than 50% stenosis are at a risk of stroke ranging from 6 to 11%, despite medical therapy. 11 According to Thijs and Albers, 46 approximately 50% of patients with severe intracranial stenosis who have neurological symptoms while receiving antithrombotic regimens will have another episode of ischemia. Endoluminal stent implantation for medically intractable or high-grade (Ͼ 70%) intracranial atherosclerotic lesions is becoming an increasingly popular intervention. 19, 20, 30, 37 Although morbidity rates following stent placement in the posterior intracranial circulation can be as high as those for surgical bypass procedures in the same region, little is known about the intracranial vascular response to endoluminal prosthetic devices (stents). 7, 23, 24, 30 
Need For an In Vivo Intracranial Stent Model
Coronary and peripheral vascular responses to endoluminal stents have been demonstrated in numerous studies. To our knowledge, however, no in vivo model has been developed to assess time-dependent changes in the histological microenvironment of stent-treated intracranial vessels. Neointimal proliferation, increased smooth-muscle cell density, and restenosis subsequent to stent-induced intimal injury have been demonstrated within 6 weeks of stent implantation in existing models. After angioplasty-related injury to the intima, a cascade of events involving the interaction of cytokines and growth factors produced by leukocytes, platelets, and damaged endothelial cells occurs in the arterial wall. This injury likely leads to cell-signaling pathways, resulting in the activation of smooth-muscle cells and their proliferation in the subintimal space. 48 The proliferation of monocytes in the arterial wall, along with the proliferation of smooth-muscle cells, has been found to coincide with neointimal proliferation during the first 3 to 8 days after iatrogenic intimal injury related to angioplasty. 39 In animal models of atherosclerosis, Geary, et al., 17 observed that
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Canine basilar artery stent implantation model 549 6 -* One of the six animals underwent a double stent placement, with an uncoated stent placed just proximal to the VBJ in its ASA, as well as a heparin-coated stent implanted in its BA. The five remaining animals each had a single stent placed in their BA, two uncoated stents and three heparin-coated ones.
† Neointimal area is calculated as stent area -lumen area. Although the measured stent area is not provided, it can be derived by subtracting the area of the media from that of the artery.
‡ Statistically significant.
leukocytes invade the fractured plaque and intima within 48 hours and smooth-muscle cells within the 1st week.
Smooth-muscle cells and the associated expressed proteoglycans are robust through Day 28 but their expression has subsided by Day 112. 16, 17 In another study 18 this group has demonstrated that cell proliferation in the neointima approaches baseline levels by Day 28 after angioplasty, based on results of immunohistochemical studies performed after the administration of bromodeoxyuridine.
The proliferative cascade following iatrogenic intimal injury to the endothelium, and potentially to the deeper arterial wall structures, can be divided into three phases as follows: 1) an acute phase that leads to initiation of the cellsignaling pathways discussed earlier (24-72 hours); 2) an intermediate phase (1-4 weeks) during which the activated medial smooth-muscle cells replicate and migrate from the media to the subintimal layer; and 3) a chronic phase (4-12 weeks) characterized by the production of large amounts of extracellular matrix, which results in further remodeling of the neointima and vessel wall. 16, 18, 38, 48 Thus, we decided to retrieve the stent-implanted vessels at 12 weeks to ensure that the chronic phase of vascular remodeling was near completion. In one dog killed 6 months after implantation of an uncoated BX Velocity stent (this animal was not included in the analyses of the results of this pilot study be- cause of the different length of follow up), in-stent stenosis (compared with the parent vessel) was 16.5% as opposed to 5.1% in the untreated adjacent arterial segment. The fact that occlusion was not greater in vessels removed at 12 weeks reinforces findings from other studies about the time-dependent changes in the histological microenvironment but provides limited information because only one animal was followed up for 6 months.
There are many peripheral and coronary stent models described in the literature, so why is it important to have a stent model for the cerebrovasculature? Intracranial vessels differ from peripheral and coronary vessels because of their paucity of adventitia, nearly absent external elastic lamina, absent vasa vasorum, thin media, multiple brainstem perforating vessels, and CSF surroundings. 28 Most importantly, it has been shown that as the VA ascends from the extracranial compartment to the BA, the composition of the arterial wall increases from 60 to 85% smooth-muscle tissue, with minimal elastic fibers. As is well described in the literature on peripheral and coronary vessels, smooth-muscle cells are the putative agents responsible for restenosis 4, 9, 10, 35 within the first few weeks after vessel injury. Thus, given the proportion of smooth-muscle cells in the BA, should we conclude that this vessel is at the highest risk of restenosis after stent placement? Although clinicians lack the answer to this and many other questions regarding intracranial stent implementation, they continue to advocate the use of endoluminal prosthetic devices (stents) in patients without in vivo modeling of the medium-and long-term effects of these devices or an understanding of potential consequences resulting from jailed perforating vessels.
Several in vitro models have demonstrated that jailed ostia of perforating vessels will remain patent if the stent strut does not entirely cover the vessel origin. 31, 32, 49, 50 Occlusion of brainstem perforating vessels resulting from an ostium jailed by a stent placed in the parent artery is potentially catastrophic. In addition to assessing the cerebrovascular response to stent-induced vascular injury, we attempted to position each BA stent over the labyrinthine and/or posterior inferior cerebellar arteries to assess the clinical, histological, and radiographic findings resulting from jailed brainstem perforating vessels. Although several sections of stent-treated arteries were obtained that demonstrated partial coverage of the brainstem perforating vessel ostia by stent struts, one section demonstrated a strut entirely covering the perforating vessel. In all cases, the perforating vessels remained patent (Fig. 7) . As previously mentioned, MR imaging in one dog (Animal 2) from the group treated with uncoated stents demonstrated ischemic injury to the left pons; however, the event was clinically silent. This image correlated with ipsilateral stenosis of the AICA. Histopathological findings in this case did not demonstrate perforating vessel occlusion.
Histopathological Differences in Vessels Treated With Heparin-Coated Stents
Using the canine BA stent model, we also attempted to ascertain whether a small number of animals could be used to examine vascular responses after endoluminal stent placement with heparin-coated and uncoated devices. The heparin-coated stent was chosen because this agent has been shown to prevent the development of subacute thrombosis. Additionally, in several animal studies it has been demonstrated that decreased neointimal proliferation, smooth-muscle cell proliferation, and restenosis (percentage of occlusion) occur after treatment with heparin during the time of stent implantation. Mechanisms of heparin-induced inhibition of restenosis include inhibition of nuclear transcription factors, modulation of growth factor activity or receptor binding, regulation of extracellular matrix production, inhibition of smooth-muscle cell proliferation, and restriction of inflammation. 40, 51 In human coronary vessels, heparin appeared to lower the rate of acute and subacute thrombosis; restenosis rates at 12 months appeared to be similar to those seen with uncoated stents. 47 Although there have been mixed results with attempts to demonstrate the effectiveness of heparin in inhibiting restenosis, we believe that the cerebrovasculature might be responsive to the antiproliferative mechanisms of heparin because 85% of the cellular composition of these vessels is smooth-muscle cells. 28 In our study, no subacute or acute stent-related thrombosis was found in either group, and at 12 weeks, based on neointimal area and thickness (p = 0.04), increased neointima/media ratio (p = 0.05), and a greater percentage of occlusion (p = 0.07), there was more neointimal proliferation in stent-implanted vessels in the group treated with uncoated devices (Fig. 10) . These results are considered likely to be of statistical significance, given the small sample size ( Table 2) . With a larger study group, these results are likely to have reached statistical significance. Additionally, there was a greater "edge effect," or stenosis of the parent vessel, immediately adjacent to the stent-implanted arteries in the group treated with uncoated devices (data not shown). Maximum smooth-muscle cell proliferation was seen in the group treated with uncoated stents; proliferation of these cells was more variable in the group treated with heparincoated stents. In all cases, the perforating vessels remained patent despite partial occlusion by stent struts.
When analyzing the data for animals treated with single stents only, greater differences were demonstrated in this group (compared with dogs receiving either one or two stents), reflecting a benefit of the heparin-coated stents with respect to neointimal area (p = 0.009), neointima/media ratio (p = 0.001), neointimal thickness (p = 0.002), and percentage of occlusion (p = 0.009), as is shown in Fig. 9 . This indicates that the coated and uncoated stents were interacting in such a way that the benefits of the heparin coating were being diminished by the uncoated stent. As shown in Fig. 9 , the values for the aforementioned parameters in the vasculature containing two stents (mixed placement) fell between those for the coated and uncoated devices. We readily admit that these findings were demonstrated in only one animal and therefore do not contribute to the reliability of the model. Nonetheless, these findings are suggestive of possible tandem stent interactions and merit further investigation.
Angiographic and MR Imaging Correlations
After a 12-week study period, six animals underwent follow-up angiography; two of them demonstrated significant stenosis of a brainstem perforating vessel (the left AICA in each case). One dog (Animal 3) had been treated with a coated device; the other (Animal 2) had received an uncoat-ed stent. The only infarct demonstrated on MR images in this study was the one in the left pontine region in Animal 2; no areas of hemorrhage were observed.
Future Applications
Newer, drug-coated stents dramatically reduced the rate of restenosis of stent-treated coronary vessels in recent clinical trials involving patients with coronary artery disease. Rapamycin-coated stents have demonstrated 0% restenosis at 6 and 12 months, compared with approximately 30% restenosis in uncoated controls. 42, 43 Taxol-coated stents have demonstrated similar results in the coronary vasculature, with 4% restenosis. 8, 22 Before such drug-coated stents can be used in the human cerebrovasculature, studies are required to measure possible absorption of the drugs into the CSF and subsequent neurotoxic effects. Future applications for the canine BA model include implantation of these newer drug-coated stents in a larger number of experimental animals and then assaying drug concentration in the CSF and monitoring canine behavior during the follow-up period. Additional studies with varying durations of endoluminal stent implantation may provide further insight into the time course of intracranial vessel restenosis.
